Lead Product(s) : RGI-2001
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : San Fu Biotech
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the terms of agreement, REGiMMUNE and SFB will collaborate closely to accelerate the development of RGI-2001 (alpha galactosylceramide liposomal), a first-in-class small molecule drug candidate, in major Asian countries for the prophylaxis of aGvHD...
Product Name : RGI-2001
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 29, 2023
Lead Product(s) : RGI-2001
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : San Fu Biotech
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : RGI-2001
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RGI-2001 is a liposomal formulation of an alpha-galactosylceramide (alpha-GalCer) analog. Alpha-GalCer is a ligand for CD1d expressed on antigen presenting cells and invariant natural killer T cells (iNKT).
Product Name : RGI-2001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 20, 2022
Lead Product(s) : RGI-2001
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RGI-2001
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RGI-2001 is a liposomal formulation of an alpha-galactosylceramide (alpha-GalCer) analog. Alpha-GalCer is a ligand for CD1d expressed on antigen presenting cells and invariant natural killer T cells (iNKT).
Product Name : RGI-2001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 11, 2022
Lead Product(s) : RGI-2001
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : UB-221
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : UB-221 shows 2 to 5-folds inhibition of IgE synthesis than Xolair in the in vitro study. UB-221 only takes 1/10 dose to achieve the same effect of Xolair in huIGHE-knock-in mice model. PK study in cynomolgus monkeys demonstrated UB-221 has a longer serum...
Product Name : UB-221
Product Type : Antibody
Upfront Cash : Inapplicable
May 27, 2022
Lead Product(s) : UB-221
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : UB-221
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : New results demonstrate a newer class of anti-IgE antibody, UB-221, with superior neutralization, synthesis reduction, and durable relief in targeting allergic diseases.
Product Name : UB-221
Product Type : Antibody
Upfront Cash : Inapplicable
May 08, 2022
Lead Product(s) : UB-221
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Burixafor Hydrobromide
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : GPCR Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
TaiGen Partners with GPCR to Develop Burixafor & Taigexyn®
Details : Under the terms of the agreement, GPCR Therapeutics will be wholly responsible for the development, registration, and commercialization of Taigexyn® in S. Korea and Burixafor worldwide.
Product Name : TG-0054
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 11, 2020
Lead Product(s) : Burixafor Hydrobromide
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : GPCR Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement